Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

not_yet_recruiting150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruiting

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

NCT06814548
recruitingphase_2

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

NCT06413017

Clinical Trials (2)

Showing 2 of 2 trials
NCT06814548

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

Not Yet Recruiting
NCT06413017Phase 2

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2